Occult hepatitis B virus infection in immunocompromised patients

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 4, 2008, Pages 300-305

  Cordeiro Moraes Jardim, Ruth Nogueira ^a   Lopes Gonçales, Neiva Sellan ^a   Felix Pereira, Josiane Silveira ^a   Fais, Viviane Cristina ^a   Lopes Gonçales Junior, Fernando ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Anti HBc alone; HBV DNA; Hemodialysis; HIV; Immunosupressed patients; Occult HBV infection

Indexed keywords

HEPATITIS B ANTIGEN; HEPATITIS C ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD DONOR; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OCCULT HEPATITIS B VIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; SEROLOGY; VIRUS LOAD;

ADULT; AGED; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LAMIVUDINE; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; VIRAL LOAD;

EID: 60649112482     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lee M.Y. Hepatitis B virus infection. N Engl J Med 1997; 24:1733-45.
2. Brechot C., Hadchouel M., Scotto J., et al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen positive and negative liver disease. Proc.Natl Acad Sci USA 1981; 78:3906-10.
3. Thiers V., Nakajima E., Kremsdorf D., et al. A transmission of hepatitis B from hepatitis B seronegative subjects. Lancet 1988;2:1273-6.
4. Wang J.T., Wang T.H., Sheu J.C., et al. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991; 163:397-9.
5. Loriot M.A., Marcellin P., Bismuth E., et al. Demonstration of hepatitis B virus DNA polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992;15:32-36.
6. Liang T.J., Baruch Y., Ben-Porath E., et al. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 1991; 13:1044-51.
7. Medrano F.J., Sanchez-Quijano A., Pineda J., Lissen E. Isolated anti-HBc and hepatitis B virus occult infection. Vox sang 1991;61:140.
8. Sanchez-Quijano A., Jauregui J.I., Leal M., et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993;17:288-93.
9. Villa E., Grottola A., Buttafoco P., et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci 1995;40:8-13.
10. Grob P., Jilg W., Bornhak H., et al. serological pattern "Anti-HBc Alone": Report on a workshop. J Med Virol 2000;62:450-5.
11. Gonçales Junior F.L., Pereira J.S.F., Silva C., et al. Hepatitis B virus DNA in sera of blood donors and of patients infected with hepatitis C virus and human immunodeficiency virus. Clin Diagn Lab Immunol 2003;10718-20.
12. Fabrizi F., Messa P.G., Lunghi G., et al. Occult hepatitis B virus in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005;21:1341-7.
13. Burdick R.A., Bragg-Gresha M.J.L., Woods J.D., et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003;63:2222-9.
14. Pastore G., Santantonio T., Monno L., et al. Effects of HIV superinfection on HBV replication in a chronic HbsAg carrier with liver disease. J Hepatol 1998;2:164-8.
15. Gilson R.J., Tedder R.S., Weller I.V. Hepatitis B: reactivation or reinfection associated with HIV-1 infection.Lancet ii:1330.
16. Hino K., Basumi A.A., Ireland J., et al. Reappearance of hepatitis B surface antigen in immunocompromised individuals:reinfection or reactivation? Dig Dis Sci 2002;47:415-8.
17. Kaneko S., Feinstone S.M., Miller R.H. Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. J Clin Microbiol 1989;27:1930-3.
18. Paterlini P., Gerken G., Nakajima E., et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Eng J Med 1990;323:80-5.
19. Baginski I., Chemin I., Hantz O., et al. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion 1992;32:215-20.
20. Pereira J.S., Gonçales N.S., Silva C., et al. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors. Braz J Med Biol Res 2006;39:525-3.
21. Fukuda R., Ishimura N., Niigaki M., et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-7.
22. Cacciola I., Pollicino T., Squadrito G., et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.
23. Silva C., Gonçales N.S., Pereira J.S., et al. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients. Braz J Infect Dis 2004;8:431-9.
24. Besiisik F., Karaca C., Akyuz F., et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003;38:506-10.
25. Puoti M., Torti C., Bruno R., et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006;44:565-70.
26. Chamorro A.J., Casado J.L., Bellido D., Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 2005;24(7):492-4.
27. Brechot C., Thiers V., Kremsdorf D., et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34(1):194-203.
28. Luo K.X., Zhou R., Liang Z.S., Jiang S.B. Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to hepatitis B core antigen. J Med Virol. 2002;35:59-9.
29. Hofer M., Joller-Jemelka H.I., Grob P.J., et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study.Eur J Clin Microbiol Infect Dis 1998;17:6-13.
30. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;1:11-20.
31. Zuckerman J.N., Zuckerman A.J. Current topics in hepatitis B. J Infect 2000;41:130-6.
32. Ackerman Z., Wands J.R., Gazitt Y., et al. Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. J Hepatol 1994; 40:398-404.
33. Dienstag J.L., Perrillo R.P., Schiff E.R., et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-61.
34. Dore G.J., Cooper D.A., Barrett C., et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180:607-13.
35. Nevens F., Main J., Honkoop P., et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
36. Benhamou Y., Katlama C., Lunel F., et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
37. Hoff J., Bani-Sadr F., Gassin M., Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-9.
38. Wolters L.M., Hansen B.E., Niesters H.G., de Man R.A. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 2002;14:1007-11.
39. Honkoop P., de Man R.A., Zondervan P.E., Schalm S.W. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;17:103-7.
40. Thibault V., Behamou Y., Seguret C., et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999;37:3013-6.